A Surrey health trust says it is to become the first in the UK to trial a drug for a debilitating eye condition.Frimley ...

One of the biggest challenges with eye cancer is that its symptoms can be subtle or even invisible at first. Regular eye ...

Proptosis, a common feature of thyroid eye disease, causes forward bulging of the eyeball due to tissue expansion within the orbit. It can impair vision, cause discomfort, and affect ...

This collaboration will focus on the design and development of a non-viral vector for the delivery of cSIRT6 to the eye, with the aim of addressing ocular diseases more effectively. Dr.

eye drops, and oral medications for inherited retinal diseases and other ophthalmic disorders. Ocuphire had an embattled pipeline. One of its assets, an oral drug for diabetic retinopathy known as ...

“Given the failure of the ZEDS [Zoster Eye Disease Study] trial to demonstrate a significant benefit in the primary outcome of new or recurrent disease, it appears difficult to give a blanket ...

Aldeyra Therapeutics shares fell 73% to $1.42 in the regular session after it reported a Food and Drug Administration complete response letter for reproxalap for treatment of dry eye disease.

Per draft FDA dry eye disease guidance, to be considered for regulatory approval in the United States, efficacy in dry eye disease may be demonstrated with two symptom trials and two sign trials.

Reproxalap, a reactive aldehyde species modulator, is approved for dry eye disease, reducing ocular redness. A phase 3 trial with 132 patients confirmed reproxalap's efficacy over a control in ...

SpliceBio, a clinical-stage genetic medicines company, announced that it has dosed the first patient in the phase ½ Astra study of SB-007, a dual adeno-associated viral vector, for the treatment of ...